Investor Relations

Stock Information.


View Detailed Stock Information

Latest News.

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

Read Press Release

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

Read Press Release

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Read Press Release

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Read Press Release

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Read Press Release

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Read Press Release

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Read Press Release

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Read Press Release

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Read Press Release

Latest Financial Results.

Q1 2025

Quarter Ended Mar 31, 2025

Latest Event.

2025 Annual Meeting of Stockholders

Company Overview.

Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

IR Contacts.

Corporate Office

VolitionRx Ltd
1489 West Warm Springs Road
Suite 110
Henderson, NV 89014
Phone: +1-702-425-1561
info@volition.com

Investor Relations

VolitionRx
Phone: +1-646-650-1351
investorrelations@volition.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Phone: +1-212-828-8436
F: +1-646-536-3179
info@vstocktransfer.com
https://www.vstocktransfer.com